Form 4 Filing: Eli Lilly & Co. Ownership Update Post-IPO

This filing details a change in beneficial ownership for Eli Lilly & Co. (ELI LILLY & Co) concerning Scribe Therapeutics, Inc. (SCTX). Following the initial public offering (IPO) of Scribe Therapeutics, Inc., Eli Lilly & Co. will no longer be considered a 10% owner. Consequently, they will be released from their Section 16 reporting obligations. The filing indicates that after the IPO, Eli Lilly & Co. will directly own 1,054,828 shares of Scribe Therapeutics, Inc. common stock. This update reflects a shift in ownership status due to the public offering.